News and Announcements
Major Biopharmaceutical Signs to Up to MedAdvisor Patient Engagement Program
- Published July 01, 2016 4:35PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st July 2016, ASX Announcement
Highlights:
- MedAdvisor is collaborating with Bristol-Myers Squibb Australia (BMS) to deliver a patient engagement and education program concerning one of its products
- Commencing shortly the 12-month patient engagement program (PEP) is being delivered via MedAdvisor’s medication management platform
- This agreement will generate further PEP revenue for MedAdvisor
- Provides further strong validation for MedAdvisor’s platform from a leading global biopharmaceutical company
MedAdvisors Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce that it will be collaborating with the Australian subsidiary of leading global pharmaceutical company, Bristol-Myers Squibb Company, to deliver a new patient engagement and education program.
To view the full announcement, please click on the button below.